Clinical trial
Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal…
NCT03381729 · Novartis Gene Therapies, Industry · Terminated
Key facts
| NCT number | NCT03381729 |
|---|---|
| Title | Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy |
| Official title | Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy |
| Acronym | STRONG |
| Lead sponsor | Novartis Gene Therapies, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Spinal Muscular Atrophy |
| Intervention type | Biological |
| Interventions | Onasemnogene Abeparvovec-xioi |
| Enrollment | 32 |
| Start date | Dec 14, 2017 |
| Primary completion | Nov 18, 2021 |
| Completion | Nov 18, 2021 |
| First posted | Dec 22, 2017 |
| Last update posted | Jan 26, 2026 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: